Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix, Inc. is a clinical-stage biopharma with two operating segments: Specialized BioTherapeutics and Public Health Solutions. The company has no approved products and reported for the six months ended June 30, 2025 a net loss of $5,653,244 and used $4,588,835 of cash in operating activities, with working capital of $1,691,345. As of June 30, 2025 the company had 3,504,950 shares issued and outstanding and significant potential dilution from 1,467,581 warrants, 300,467 options (112,332 vested) and 5,929,412 shares available under the 2025 Equity Incentive Plan. Recent financing activity included issuance of 780,620 ATM shares at a weighted average price of $1.84 for gross proceeds of ~$1.44M. Management expects to pursue additional equity, grant/contract funding, partnerships, or other strategic transactions but states uncertainty about obtaining sufficient capital. The filing discloses an auditor going-concern opinion and substantial risks tied to government funding, clinical/regulatory outcomes, third-party manufacturing, and market acceptance.
Soligenix, Inc. reported that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted orphan drug designation to dusquetide, the active ingredient in its drug candidate SGX945, for the treatment of Behçet’s Disease. This decision follows review of recent Phase 2a clinical results that showed biological efficacy and safety in patients with Behçet’s Disease.
The company highlighted that this regulatory milestone is based on early-stage clinical data and cautioned that forward-looking statements are subject to significant risks and uncertainties described in its periodic SEC reports.
Soligenix, Inc. reported that it received a notice from Nasdaq on August 15, 2025 stating the company no longer meets the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market. In its Form 10-Q for the quarter ended June 30, 2025, Soligenix reported stockholders’ equity of $1,828,951, below this threshold, although this figure does not include gross proceeds of approximately $1,439,300 from sales under its At-The-Market facility on July 1, 2025.
The company also does not satisfy Nasdaq’s alternative continued listing standards based on market value or net income. The notice does not immediately affect trading, and the stock continues to trade on Nasdaq under the symbol SNGX. Soligenix has 45 calendar days, until September 29, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to evidence compliance. If the plan is not accepted or compliance is not regained, the company’s common stock could become subject to delisting, with the possibility of an appeal to a Nasdaq Hearings Panel.
Form 4 filing reveals that Anthony Gregg Lapointe, Director of Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This grant represents standard director compensation and indicates continued board engagement. The 10-year option term provides long-term alignment with shareholder interests.
Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.
The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:
- September 20, 2025
- December 20, 2025
- March 20, 2026
- June 20, 2026
This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.
Form 4 filing reveals that Robert J. Rubin, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This equity compensation grant aligns the director's interests with shareholders through a standard 10-year term and quarterly vesting schedule over one year. The transaction was reported in compliance with SEC Section 16 requirements for insider trading disclosure.
Form 4 filing reveals that Diane L. Parks, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 17,647 stock options to purchase common stock
- Exercise price set at $1.70 per share
- Options expire on June 20, 2035
- Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026
This stock option grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The 10-year exercise period provides significant time value for these options.
Soligenix has filed a Form S-8 to register securities under its 2025 Equity Incentive Plan. The company, headquartered in Princeton, New Jersey, is classified as both a non-accelerated filer and a smaller reporting company.
Key filing incorporations include:
- Annual Report on Form 10-K for FY2024 (filed March 21, 2025)
- Q1 2025 Form 10-Q (filed May 9, 2025)
- Recent Form 8-K filings from February, March, and June 2025
The registration includes comprehensive indemnification provisions for directors and officers under Delaware law, including protection against personal liability for fiduciary duty breaches, except in cases of:
- Breach of duty of loyalty
- Acts not in good faith or involving intentional misconduct
- Unlawful dividend payments or stock repurchases
- Improper personal benefit transactions